Lipophilic bisphosphonates used to target lung cancer

Lipophilic bisphosphonates, originally used to treat osteoporosis, has demonstrated efficacy against lung adenocarcinoma (pictured).

Bisphosphonates are used to treat osteoporosis and other disorders of bone resorption. A new generation of lipophilic bisphosphonates has been designed to target cancer; one such agent, BPH-1222, a zoledronic acid analogue, has demonstrated efficacy against lung adenocarcinoma.

According to research in Science Translational Medicine (2014;6:263ra161)[1]
, BPH-1222 was significantly more effective than the most potent standard bisphosphonate in killing tumour cells with KRAS mutations both in vitro and in a mouse model. A combination of BPH-1222 and rapamycin (sirolimus) was more effective than either agent alone in facilitating autophagy and inhibiting tumour growth.

“Using lipophilic bisphosphonates in combination with rapamycin may provide an effective strategy for targeting lung adenocarcinomas harbouring KRAS mutations,” write Yifeng Xia, from Salk Institute for Biological Studies, La Jolla, California, and colleagues.

References

[1] Xia Y, Liu Y-L, Xie Y et al. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci Transl Med 2014;6:263ra161. doi:10.1126/scitranslmed.3010382.

Last updated
Citation
The Pharmaceutical Journal, PJ, 6/13 December 2014, Vol 293, No 7839/40;293(7839/40):DOI:10.1211/PJ.2014.20067226